ITOS - iTeos Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
ITOS price evolution
ITOS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $251.4 | $146.92 | $251.45 | |
| Short term investments | $320.16 | $302.5 | $280.74 | |
| Net receivables | $42.8 | $35.39 | $0.13 | $6.5 |
| Inventory | ||||
| Total current assets | $544.88 | $626.61 | $480.39 | $550.65 |
| Long term investments | $107.85 | $132.59 | $100.54 | |
| Property, plant & equipment | $10.89 | $10.83 | $11.07 | $10.73 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $125.24 | $149.38 | $116.94 | |
| Total investments | $428 | $435.08 | $381.28 | |
| Total assets | $723.08 | $751.84 | $629.77 | $667.59 |
| Current liabilities | ||||
| Accounts payable | $7.15 | $11.05 | $11.6 | $21.08 |
| Deferred revenue | $1.6 | $1.18 | $2.06 | |
| Short long term debt | $1.28 | $1.26 | $1.25 | |
| Total current liabilities | $36.81 | $34.67 | $35.56 | $40.01 |
| Long term debt | $4.24 | $4.56 | $4.81 | |
| Total noncurrent liabilities | $53.31 | $53.01 | $52.35 | |
| Total debt | $5.52 | $5.82 | $6.06 | |
| Total liabilities | $91.39 | $87.97 | $88.57 | $92.36 |
| Shareholders' equity | ||||
| Retained earnings | $33.93 | $79.29 | $86.42 | $124.63 |
| Other shareholder equity | -$10.97 | -$16.56 | -$16.34 | -$13.24 |
| Total shareholder equity | $663.87 | $541.2 | $575.23 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $251.45 | $285.04 | $848.84 | $336.45 |
| Short term investments | $280.74 | $328.36 | ||
| Net receivables | $6.5 | $2.44 | $4.02 | $0.13 |
| Inventory | ||||
| Total current assets | $550.65 | $628.3 | $874.71 | $339.54 |
| Long term investments | $100.54 | $118.22 | ||
| Property, plant & equipment | $10.73 | $6.77 | $7.4 | $1.35 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $116.94 | $126.69 | $10 | $5.01 |
| Total investments | $381.28 | $446.58 | ||
| Total assets | $667.59 | $754.99 | $884.71 | $344.56 |
| Current liabilities | ||||
| Accounts payable | $21.08 | $7.66 | $5.14 | $3.03 |
| Deferred revenue | $2.06 | $13.78 | $281.05 | $4.49 |
| Short long term debt | $1.25 | $0.84 | $0.77 | |
| Total current liabilities | $40.01 | $42 | $304.12 | $15 |
| Long term debt | $4.81 | $3.84 | $4.57 | |
| Total noncurrent liabilities | $52.35 | $49.66 | $27.77 | $6.36 |
| Total debt | $6.06 | $4.67 | $5.34 | |
| Total liabilities | $92.36 | $91.66 | $331.89 | $21.36 |
| Shareholders' equity | ||||
| Retained earnings | $124.63 | $237.28 | $140.62 | -$73.9 |
| Other shareholder equity | -$13.24 | -$9.64 | -$1.02 | $0.62 |
| Total shareholder equity | $575.23 | $663.33 | $552.82 | $323.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $35 | |||
| Cost of revenue | ||||
| Gross Profit | $35 | |||
| Operating activities | ||||
| Research & development | $36.71 | $34.53 | $27.78 | |
| Selling, general & administrative | $12.46 | $12.7 | $12.37 | |
| Total operating expenses | $48.8 | $49.17 | $47.23 | $40.15 |
| Operating income | -$14.17 | -$47.23 | -$40.15 | |
| Income from continuing operations | ||||
| EBIT | -$4.87 | -$36 | -$28.19 | |
| Income tax expense | $2.24 | $2.26 | $2.21 | $2.36 |
| Interest expense | $8.01 | |||
| Net income | ||||
| Net income | -$45.36 | -$7.13 | -$38.22 | -$30.55 |
| Income (for common shares) | -$7.13 | -$38.22 | -$30.55 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12.6 | $267.63 | $344.77 | |
| Cost of revenue | ||||
| Gross Profit | $12.6 | $267.63 | $344.77 | |
| Operating activities | ||||
| Research & development | $113.3 | $97.36 | $59.37 | $29.9 |
| Selling, general & administrative | $50.4 | $43.95 | $40.51 | $15.34 |
| Total operating expenses | $163.7 | $141.31 | $99.87 | $45.24 |
| Operating income | -$151.1 | $126.32 | $244.9 | -$45.24 |
| Income from continuing operations | ||||
| EBIT | -$109.03 | $148.74 | $256.46 | -$38.09 |
| Income tax expense | $3.61 | $52.08 | $41.94 | -$0.06 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$112.64 | $96.65 | $214.52 | -$38.03 |
| Income (for common shares) | -$112.64 | $96.65 | $214.52 | -$43.4 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$7.13 | -$38.22 | -$30.55 | |
| Operating activities | ||||
| Depreciation | $0.31 | $0.3 | $0.23 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.06 | $7.26 | $7.19 | |
| Total cash flows from operations | -$33.93 | -$32.4 | -$13.77 | |
| Investing activities | ||||
| Capital expenditures | -$0.44 | -$0.94 | -$1.4 | |
| Investments | $16.76 | -$68.66 | $62.97 | |
| Total cash flows from investing | -$144.77 | $16.32 | -$69.6 | $61.56 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $122.38 | $0.02 | $0.31 | |
| Net borrowings | ||||
| Total cash flows from financing | $121.96 | $122.38 | $0.02 | $0.31 |
| Effect of exchange rate | -$0.91 | -$0.29 | -$2.55 | -$1.05 |
| Change in cash and equivalents | -$127.4 | $104.48 | -$104.53 | $47.05 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$112.64 | $96.65 | $214.52 | -$38.03 |
| Operating activities | ||||
| Depreciation | $0.9 | $0.8 | $0.6 | $0.54 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $27.02 | $21.56 | $13.79 | $4.29 |
| Total cash flows from operations | -$103.76 | -$111.19 | $513.14 | -$25.18 |
| Investing activities | ||||
| Capital expenditures | -$2.97 | -$0.94 | -$1.18 | -$0.36 |
| Investments | $75.72 | -$445 | ||
| Total cash flows from investing | $72.66 | -$446.06 | -$1.24 | -$0.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.11 | $0.93 | $2.94 | $211.27 |
| Net borrowings | ||||
| Total cash flows from financing | $1.11 | $1.98 | $3.66 | $340.34 |
| Effect of exchange rate | -$3.6 | -$8.53 | -$3.18 | $1.68 |
| Change in cash and equivalents | -$33.59 | -$563.8 | $512.38 | $316.46 |
News
Fundamentals
| Market cap | $370.75M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 36.53M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$121.25M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -3.06 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.32 |
|---|---|
| ROA | -17.50% |
| ROE | N/A |
| Debt/Equity | 0.16 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 14.80 |
| Quick ratio | N/A |